Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression
Hikmat Permana, Theo Audi Yanto, Timotius Ivan Hariyanto
Diabetes Research and Clinical Practice (2022) Vol. 195, pp. 110205-110205
Open Access | Times Cited: 20

Showing 20 citing articles:

Efficacy and safety of tixagevimab‐cilgavimab as pre‐exposure prophylaxis for COVID‐19: A systematic review and meta‐analysis
Arto Yuwono Soeroto, Theo Audi Yanto, Andree Kurniawan, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 2
Closed Access | Times Cited: 33
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Amr E. Abbas, Fatima Abbas, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 12, pp. 905-914
Open Access | Times Cited: 21
The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis
Shaymaa Glhoom, Aya Fergany, Dina El-Araby, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 8
SGLT2 Inhibitors in COVID-19: Umbrella Review, Meta-Analysis, and Bayesian Sensitivity Assessment
Vinay Suresh, Muhammad Aaqib Shamim, Victor Ghosh, et al.
Diseases (2025) Vol. 13, Iss. 3, pp. 67-67
Open Access
Non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression
Andree Kurniawan, Timotius Ivan Hariyanto
Narra J (2023) Vol. 3, Iss. 1, pp. e102-e102
Open Access | Times Cited: 13
The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies
Zhi-Hui Song, Qiao-Ming Huang, Shan-Shan Xu, et al.
Therapeutic Innovation & Regulatory Science (2024) Vol. 58, Iss. 4, pp. 773-787
Closed Access | Times Cited: 3
Long COVID as a Disease of Accelerated Biological Aging: An Opportunity to Translate Geroscience Interventions
Areez Shafqat, Mary Clare Masters, Utkarsh Tripathi, et al.
Ageing Research Reviews (2024) Vol. 99, pp. 102400-102400
Closed Access | Times Cited: 3
An Updated Prioritization of Geroscience- Guided FDA-Approved Drugs Repurposed to Target Aging
Michael Leone, Nir Barzilai
Medical Research Archives (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 2
Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19
Carmen Tisch, Eleni Xourgia, Aristomenis K. Exadaktylos, et al.
Endocrine (2024) Vol. 85, Iss. 2, pp. 660-675
Open Access | Times Cited: 2
Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy
Jelena Dimnjaković, Tamara Buble, Pero Ivanko, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Acute COVID-19 Management in Heart Failure Patients: A Specific Setting Requiring Detailed Inpatient and Outpatient Hospital Care
Alberto Palazzuoli, Matteo Beltrami, Peter A. McCullough
Biomedicines (2023) Vol. 11, Iss. 3, pp. 790-790
Open Access | Times Cited: 5
Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis
Jelena Dimnjaković, Tamara Buble, Pero Ivanko, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0301056-e0301056
Open Access | Times Cited: 1
The impact of innovative glucose-lowering drugs on the course and outcome of COVID-19 in patients with type 2 diabetes mellitus
Т. Н. Маркова, M. Stas
Diabetes Mellitus (2024) Vol. 27, Iss. 2, pp. 174-184
Open Access | Times Cited: 1
Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy
Vincenzo Maria Monda, Claudio Voci, Felice Strollo, et al.
Diabetes Therapy (2023) Vol. 14, Iss. 12, pp. 2127-2142
Open Access | Times Cited: 3
COVID-19 Vaccination and Its Relation to New-Onset Diabetes: A Narrative Review
Deepa Rashmi Sivaprakasam, Harrison Obinna Ohiri, Mohammad Shahzad Asif, et al.
Cureus (2023)
Open Access | Times Cited: 2
Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?
Medine Cumhur Cüre, Erkan Cüre
Current Pharmaceutical Design (2024) Vol. 30, Iss. 15, pp. 1149-1156
Closed Access
SGLT2 Inhibitors in COVID-19: Umbrella Review, Meta-analysis, and Bayesian Sensitivity Assessment
Vinay Suresh, Muhammad Aaqib Shamim, Victor Ghosh, et al.
Research Square (Research Square) (2024)
Open Access
Sodium–glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective
André Scheen
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 10, pp. 685-687
Closed Access
Impact of blood glucose control on clinical outcomes in type 2 diabetes patients hospitalized with COVID-19 infection
Elena Chertok Shacham, Nimra Maman, Avraham Ishay
Diabetes and Vascular Disease Research (2024) Vol. 21, Iss. 6
Open Access
Empagliflozin in adults hospitalised with COVID-19: a (null) hypothesis for RECOVERY
Monia Garofolo, Giuseppe Penno
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 12, pp. 880-881
Open Access
Page 1

Scroll to top